RT Journal Article
SR Electronic
T1 Increasing SARS-CoV-2 mutations against vaccination-acquired immunity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.30.22270133
DO 10.1101/2022.01.30.22270133
A1 Konishi, Tomokazu
YR 2022
UL http://medrxiv.org/content/early/2022/02/14/2022.01.30.22270133.abstract
AB Monovalent vaccines using RNA or adenoviruses have successfully controlled the COVID-19 epidemic in many countries. However, viral mutations have hampered the efficacy of this approach. The Omicron variant, in particular, has caused a pandemic which has put pressure on the healthcare system worldwide. Therefore, administration of booster vaccinations has been initiated; however, there are concerns about their effectiveness, sustainability, and possible dangers. There is also the question of how a variant with such isolated mutations originated and whether this is likely to continue in the future. Here, we compare the mutations in the Omicron variant with others by direct PCA to consider questions pertaining to their evolution and characterisation. The Omicron variant, like the other variants, has mutated in its human vectors. The accumulated mutations exceeded the range of acquired immunity, causing a pandemic, and similar mutations are likely to occur in the future. We also compare Omicron with variants that have infected animals and discuss the possibility of a vaccine using a weaker variant of the virus.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://github.com/TomokazuKonishi Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at Figshare https://doi.org/10.6084/m9.figshare.19029653.v1 https://doi.org/10.6084/m9.figshare.19029653.v1